Oncopeptides has a contractual obligation to deliver warrants to the EIB upon disbursement of a loan under the renewed loan facility agreement that was entered into with the EIB on 25 November 2022 (the “Loan Agreement”). Under the Loan Agreement, Oncopeptides has delivered in total 2,502,907 warrants to the EIB. According to the terms of the Loan Agreement, the EIB shall be entitled to a percentage of Oncopeptides before and after the rights issue which was completed on 15 September 2025. Existing warrants are recalculated according to the terms of the warrants and Oncopeptides has now issued an additional 285,509 warrants to itself and subsequently transferred 285,509 warrants to the EIB. In total, the EIB holds 2,788,416 warrants which entitle to in total 3,383,326 ordinary shares.

The board of directors of Oncopeptides has issued the warrants based on the authorization granted by the annual general meeting on 22 May 2025. The reason for the deviation from the shareholders’ preferential rights is to enable delivery of warrants to the EIB in accordance with the terms of the Loan Agreement. The warrants have a term of approximately 18 years and entitle the holder to subscribe for new ordinary shares in the company at a subscription price corresponding to the share’s quota value. Upon full subscription of all 2,788,416 warrants currently held by EIB, the company’s registered share capital will increase by approximately SEK 375,925.13 and the number of shares by 3,383,326 ordinary shares.